Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
After third-quarter revenue drop, Baidu warns China ad curbs to hit fourth-qu...
27 Oct 2016 at 10:00pm
By Catherine Cadell and Paul Carsten BEIJING (Reuters) - Chinese internet search giant Baidu Inc warned investors fourth-quarter revenue will slide, hitting shares, as a government crackdown on healthcare advertising that tipped the firm into its first-ever quarterly sales drop bites even harder. Baidu said revenue could slip as much as 4.6 percent in the October-December period, following the 0.7 percent third-quarter drop it reported on Thursday. Earlier this year it was at the center of a national media outcry when a student with a fatal cancer blamed Baidu ads for directing him to suspect, ultimately ineffectual treatment.
Myanmar detects first Zika infection
27 Oct 2016 at 8:58pm
Myanmar has detected its first Zika infection with state media reporting Friday that a pregnant foreign woman had been diagnosed with the mosquito-borne virus. The World Health Organization warned earlier this month that Zika was likely to spread throughout Asia after being detected in 70 countries worldwide, including at least 19 in the Asia Pacific region. While the virus linked to birth defects has been present in Southeast Asia for years, there has been an uptick in the number of recorded cases in the region in recent months.
World Bank appoints first adviser to tackle LGBTI discrimination
27 Oct 2016 at 8:51pm
By Sebastien Malo NEW YORK (Thomson Reuters Foundation) - The World Bank has appointed its first adviser tasked with promoting the lesbian, gay, bisexual, transgender and intersex (LGBTI) issues in its development work. The newly created senior position is part of the bank's efforts to solidify its commitment to researching and curbing discrimination against LGBTI persons across the 136 countries where it has offices, it said on Thursday. The initiative by the poverty-fighting institution comes at a time when discrimination against LGBTI people is facing increased scrutiny globally.
Health law consumers face least choice in program's history
27 Oct 2016 at 7:20pm
WASHINGTON (AP) ? Americans in the health insurance markets created by President Barack Obama's law will have less choice next year than any time since the program started, a new county-level analysis for The Associated Press has found.
GE in discussion with Baker Hughes on potential partnerships
27 Oct 2016 at 5:13pm
Baker Hughes shares, which had jumped nearly 14 percent in extended trading after the Wall Street Journal had reported that General Electric was in talks to buy the company, pared some gains and were up about 7 percent. The Journal had reported that GE has approached Baker Hughes about a takeover. Baker Hughes, which has a market capitalization of $23.1 billion, declined to comment.
GE explores acquisition of Baker Hughes: source
27 Oct 2016 at 4:23pm
It is not clear whether Baker Hughes will engage further in deal talks, the person told Reuters. Baker Hughes, which has a market capitalization of $23.1 billion, declined to comment. Baker Hughes shares were up 13.7 percent at $62 in after-hours trading.
Obama rallies Obamacare troops at 'critical time' for program
27 Oct 2016 at 3:04pm
By Roberta Rampton WASHINGTON (Reuters) - President Barack Obama on Thursday urged more than 25,000 volunteers and advocates who dialed in to a White House conference call to pull out the stops to boost the number of people signing up for Obamacare health insurance plans. Obama warned it will be challenging to overcome the skepticism about the plans given an onslaught of headlines about surging premium prices, but he said the stakes are high. Americans who do not receive health insurance through their employer or through Medicare or Medicaid programs shop online for subsidized insurance plans starting Nov. 1 until the end of January.
Judge lets Flint residents' lawsuit against state move ahead
27 Oct 2016 at 3:02pm
LANSING, Mich. (AP) ? A Michigan judge ruled in favor of Flint residents who filed a class-action lawsuit against the state and state officials over the city's lead-contaminated water, rejecting a motion to dismiss the case entirely.
Screen time, phone use linked to less sleep for teens
27 Oct 2016 at 2:28pm
By Madeline Kennedy (Reuters Health) - Digital distractions, and a more classical one, talking on the phone, are linked to shorter sleeping time and greater daytime sleepiness for teens, Canadian researchers say. ?Today?s adolescents sleep much less than previous generations, their sleep quality is poorer, and they report more daytime sleepiness, all of which have health and social consequences,? said Jennifer O?Loughlin, an author of the paper in the journal Sleep Health and researcher at the University of Montreal. At the same time, electronic media are becoming a larger part of teen?s lives and are often used before bed, O?Loughlin told Reuters Health by email.
Worth it? A faster transplant but a kidney with hepatitis C
27 Oct 2016 at 1:31pm
WASHINGTON (AP) ? A bold experiment is giving some patients a chance at cutting years off their wait for a kidney transplant if they agree to a drastic-sounding option ? getting an organ almost sure to infect them with hepatitis C.
Veterans may face higher risk of suicide during first year home
27 Oct 2016 at 1:00pm
By Lisa Rapaport (Reuters Health) - Veterans may be more likely to commit suicide during the first year after they leave the military than after more time passes, a U.S. study suggests. Compared with people still on active duty in the military, veterans out of the service for up to three months were 2.5 times more likely to commit suicide, the study found. Veterans who had left the service from three to 12 months earlier had almost triple the suicide odds of current members of the military.
Scientists identify fossilized dinosaur brain tissue for first time
27 Oct 2016 at 12:45pm
British and Australian scientists have identified an unassuming brown pebble, found more than a decade ago by a fossil hunter in southern England, as the first known example of fossilized dinosaur brain tissue. The fossilized brain, found by fossil enthusiast Jamie Hiscocks near Bexhill in Sussex in 2004, is most likely from a species similar to Iguanodon - a large herbivore that lived during the early cretaceous period, some 133 million years ago. In a report of their analysis in a Special Publication of the Geological Society of London, the researchers said they believed this piece of tissue was so well-preserved because the dinosaur's brain was "pickled" in a highly acidic and low-oxygen body of water ? like a bog or swamp ? shortly after it died.
Have a kid with migraines? Sugar pills work as well as drugs
27 Oct 2016 at 12:06pm
CHICAGO (AP) ? Sugar pills worked as well at preventing kids' migraines as two commonly used headache medicines, but had fewer side effects, in a study that may lead doctors to rethink how they treat a common ailment in children and teens.
People in Florida's latest Zika 'hot zone' want more buzz
27 Oct 2016 at 11:53am
MIAMI (AP) ? Mosquitoes bite everyone, not just Haitians. It's a point health educator Marie-Jose Ledan is sure to make when she approaches Little Haiti's churches, laundromats and mom-and-pop businesses about protecting people from the Zika virus.
More evidence cranberries don't prevent urinary tract infections
27 Oct 2016 at 11:39am
By Andrew M. Seaman (Reuters Health) - Over the course of a year, taking cranberry capsules did nothing to stave off urinary tract infections (UTIs) among older women living in nursing homes, a U.S. study finds. "I think it reinforces what many of the other studies have said so far," said lead author Dr. Manisha Juthani-Mehta, of the Yale School of Medicine in New Haven, Connecticut. Previous studies on the use of cranberry products like juice and capsules produced mixed results.